GSA Capital Companions LLP purchased a brand new place in shares of Insulet Co. (NASDAQ:PODD – Free Report) throughout the third quarter, in accordance with its most up-to-date disclosure with the Securities & Change Fee. The institutional investor purchased 4,370 shares of the medical devices provider’s inventory, valued at roughly $1,017,000.
Different giant buyers additionally lately modified their holdings of the corporate. Marshall Wace LLP purchased a brand new place in Insulet within the 2nd quarter valued at about $99,978,000. Baillie Gifford & Co. lifted its holdings in shares of Insulet by 30.8% within the second quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical devices provider’s inventory valued at $380,607,000 after buying an extra 443,783 shares within the final quarter. Canada Pension Plan Funding Board boosted its place in shares of Insulet by 206.9% throughout the first quarter. Canada Pension Plan Funding Board now owns 429,591 shares of the medical devices provider’s inventory valued at $73,632,000 after shopping for an extra 289,591 shares over the last quarter. Vanguard Group Inc. grew its holdings in Insulet by 2.1% throughout the first quarter. Vanguard Group Inc. now owns 8,199,114 shares of the medical devices provider’s inventory price $1,405,328,000 after shopping for an extra 169,506 shares within the final quarter. Lastly, First Mild Asset Administration LLC bought a brand new stake in Insulet within the 1st quarter valued at $25,927,000.
Insulet Inventory Down 0.4 %
Shares of NASDAQ:PODD opened at $260.12 on Friday. The agency has a fifty day transferring common of $237.77 and a 200 day transferring common of $207.47. Insulet Co. has a 52-week low of $160.19 and a 52-week excessive of $279.40. The corporate has a debt-to-equity ratio of 1.21, a fast ratio of two.80 and a present ratio of three.68. The agency has a market capitalization of $18.25 billion, a PE ratio of 44.54, a price-to-earnings-growth ratio of 4.11 and a beta of 1.22.
Wall Avenue Analyst Weigh In
PODD has been the topic of a number of current analyst stories. Piper Sandler upped their goal worth on shares of Insulet from $230.00 to $285.00 and gave the inventory an “obese” ranking in a analysis observe on Tuesday, September seventeenth. UBS Group elevated their worth goal on shares of Insulet from $211.00 to $223.00 and gave the corporate a “impartial” ranking in a analysis observe on Friday, August ninth. Canaccord Genuity Group boosted their goal worth on Insulet from $236.00 to $269.00 and gave the inventory a “purchase” ranking in a analysis observe on Wednesday, September twenty fifth. Sanford C. Bernstein assumed protection on Insulet in a analysis report on Wednesday, November sixth. They set an “outperform” ranking and a $300.00 worth goal for the corporate. Lastly, BTIG Analysis boosted their worth goal on Insulet from $260.00 to $270.00 and gave the inventory a “purchase” ranking in a analysis report on Friday, November eighth. Three analysts have rated the inventory with a maintain ranking and twelve have assigned a purchase ranking to the inventory. In line with MarketBeat.com, the inventory presently has a consensus ranking of “Average Purchase” and a consensus goal worth of $253.27.
Get Our Newest Analysis Report on Insulet
About Insulet
Insulet Company develops, manufactures, and sells insulin supply programs for individuals with insulin-dependent diabetes. The corporate’s Omnipod platform contains the Omnipod 5 Automated Insulin Supply System (Omnipod 5) which features a proprietary AID algorithm embedded within the Pod that integrates with a third-party steady glucose monitor to acquire glucose values by means of wi-fi bluetooth communication; Omnipod DASH that encompasses a bluetooth enabled Pod that’s managed by a smartphone-like Private Diabetes Supervisor with a colour contact display consumer interface; and Omnipod GO, a standalone, wearable, insulin supply system that gives a hard and fast price of steady rapid-acting insulin for 72 hours.
Learn Extra
Wish to see what different hedge funds are holding PODD? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Insulet Co. (NASDAQ:PODD – Free Report).
Obtain Information & Scores for Insulet Day by day – Enter your e-mail handle under to obtain a concise each day abstract of the most recent information and analysts’ scores for Insulet and associated corporations with MarketBeat.com’s FREE each day e-mail publication.
